RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

• click to rate

  Posted by Two Blokes Jul 10 - Filed in Stock - 7 views
  
  Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.